Profile data is unavailable for this security.
About the company
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.
- Revenue in USD (TTM)0.00
- Net income in USD-23.25m
- Incorporated2013
- Employees32.00
- LocationMatinas BioPharma Holdings IncSuite 302, 1545 Route 206 SouthBEDMINSTER 07921United StatesUSA
- Phone+1 (908) 443-1860
- Fax+1 (302) 636-5454
- Websitehttps://www.matinasbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mink Therapeutics Inc | 0.00 | -20.59m | 38.78m | 31.00 | -- | -- | -- | -- | -0.5964 | -0.5964 | 0.00 | -0.585 | 0.00 | -- | -- | 0.00 | -175.32 | -- | -3,661.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| DURECT Corp | 8.32m | -23.28m | 39.11m | 48.00 | -- | 4.71 | -- | 4.70 | -0.8653 | -0.8653 | 0.2976 | 0.2674 | 0.176 | 0.7021 | 6.87 | 143,465.50 | -49.23 | -37.34 | -167.81 | -53.44 | 80.56 | 91.83 | -279.77 | -139.11 | 0.9575 | -47.70 | 0.6377 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Xilio Therapeutics Inc | 0.00 | -70.96m | 39.50m | 73.00 | -- | 1.43 | -- | -- | -2.57 | -2.57 | 0.00 | 0.7474 | 0.00 | -- | -- | 0.00 | -73.11 | -- | -96.98 | -- | -- | -- | -- | -- | -- | -144.29 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Bright Green Corp | 0.00 | -13.13m | 39.92m | 5.00 | -- | 3.54 | -- | -- | -0.0732 | -0.0732 | 0.00 | 0.0594 | 0.00 | -- | -- | 0.00 | -64.24 | -- | -97.68 | -- | -- | -- | -- | -- | -- | -5,488.51 | 0.0181 | -- | -- | -- | 52.54 | -- | -- | -- |
| Cara Therapeutics Inc | 16.94m | -122.54m | 40.12m | 55.00 | -- | 1.35 | -- | 2.37 | -2.26 | -2.26 | 0.3118 | 0.5452 | 0.1392 | 1.34 | 4.35 | 307,963.60 | -100.70 | -35.76 | -115.83 | -40.82 | 75.18 | -- | -723.49 | -162.10 | 5.20 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Natural Alternatives International, Inc. | 120.20m | -3.31m | 40.31m | 317.00 | -- | 0.4793 | 30.03 | 0.3353 | -0.5646 | -0.5646 | 20.53 | 13.56 | 0.8091 | 3.63 | 12.77 | 379,183.00 | -2.23 | 4.90 | -2.56 | 5.93 | 8.85 | 15.98 | -2.75 | 3.80 | 2.44 | -2.71 | 0.0996 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -40.09m | 40.48m | 15.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0482 | 0.00 | -- | -- | 0.00 | -303.75 | -- | -1,499.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -15.53m | 40.51m | 29.00 | -- | -- | -- | -- | -0.3227 | -0.3227 | 0.00 | -0.0811 | 0.00 | -- | -- | 0.00 | -276.90 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| Movano Inc | 852.00k | -27.91m | 40.58m | 30.00 | -- | -- | -- | 47.63 | -0.5593 | -0.5593 | 0.0168 | -0.0263 | 0.0779 | -- | 2.12 | 28,400.00 | -254.99 | -151.50 | -559.26 | -188.58 | -42.61 | -- | -3,275.47 | -- | 0.5147 | -- | -- | -- | -- | -- | 3.45 | -- | 4.24 | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.05m | 41.35m | 4.00 | -- | 6.86 | -- | -- | -1.17 | -1.17 | 0.00 | 0.3807 | 0.00 | -- | -- | 0.00 | -194.65 | -- | -283.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -23.25m | 41.38m | 32.00 | -- | 2.46 | -- | -- | -0.107 | -0.107 | 0.00 | 0.0669 | 0.00 | -- | -- | 0.00 | -80.36 | -44.62 | -86.16 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.0014 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
| Hcw Biologics Inc | 3.93m | -27.39m | 41.61m | 45.00 | -- | 4.76 | -- | 10.60 | -0.7547 | -0.7547 | 0.1083 | 0.2311 | 0.1062 | -- | 6.79 | 87,258.22 | -74.07 | -- | -97.78 | -- | 29.61 | -- | -697.59 | -- | -- | -146.89 | 0.4863 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Immuneering Corp | 0.00 | -54.18m | 42.11m | 65.00 | -- | 0.5349 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Incannex Healthcare Inc | -100.00bn | -100.00bn | 42.86m | -- | -- | 3.03 | -- | -- | -- | -- | -- | 0.8907 | -- | -- | -- | -- | -- | -54.94 | -- | -59.47 | -- | -- | -- | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| Benson Hill Inc | 359.83m | -132.72m | 42.93m | 270.00 | -- | 0.6379 | -- | 0.1193 | -0.7033 | -0.7082 | 1.90 | 0.3174 | 1.13 | 9.80 | 20.67 | 1,332,689.00 | -41.85 | -- | -49.16 | -- | 5.38 | 3.18 | -36.88 | -40.73 | 2.02 | -2.12 | 0.183 | -- | 24.16 | 156.43 | -11.58 | -- | 63.78 | -- |
| CASI Pharmaceuticals Inc | 28.94m | -30.48m | 43.42m | 176.00 | -- | 2.81 | -- | 1.50 | -2.28 | -2.28 | 2.16 | 1.15 | 0.3954 | 1.00 | 3.41 | 164,437.50 | -40.88 | -34.75 | -59.15 | -46.91 | 58.36 | 55.98 | -103.40 | -153.72 | 3.25 | -76.70 | 0.5458 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
Data as of May 24 2024. Currency figures normalised to Matinas BioPharma Holdings Inc's reporting currency: US Dollar USD
9.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 9.25m | 3.69% |
| Sargent Investment Group LLCas of 31 Mar 2024 | 3.61m | 1.44% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.48m | 0.99% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.14m | 0.85% |
| Arkadios Wealth Advisors LLCas of 31 Mar 2024 | 1.62m | 0.65% |
| Neville, Rodie & Shaw, Inc.as of 31 Mar 2024 | 1.16m | 0.46% |
| JTC Plc /Private Banking/as of 31 Mar 2024 | 775.00k | 0.31% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 659.87k | 0.26% |
| LPL Financial LLCas of 31 Mar 2024 | 612.33k | 0.24% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 430.65k | 0.17% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
